Top

Neurological Sciences

Published in:

01-02-2019 | Review Article

Efficacy and safety of edaravone in treatment of amyotrophic lateral sclerosis—a systematic review and meta-analysis

Authors: Linting Luo, Zhibin Song, Xiaoqiang Li, Huiwang, Yaqing Zeng, Qinwang, Meiqi, Jianli He

Published in: Neurological Sciences | Issue 2/2019

Abstract

Background

Based on the results of randomized, double-blind, placebo-controlled trials, the benefit and safety of edaravone in the treatment of amyotrophic lateral sclerosis remain controversial. We performed a meta-analysis to evaluate the efficacy and safety of edaravone in the treatment of this disease.

Methods

We searched PubMed, the Cochrane Library, and Embase from the inception of electronic data to April 2018. We included randomized, double-blind, placebo-controlled trials reporting amyotrophic lateral sclerosis patients receiving 60-mg intravenous edaravone or intravenous saline placebo for 24 weeks. The primary efficacy evaluation was changed in Amyotrophic Lateral Sclerosis Functional Rating Scale score from baseline to after the trial. Measure of safety was the frequency of investigated adverse events and serious adverse events. Data synthesis and analysis and evaluation of risk of bias were performed using RevMan 5.3 software. Heterogeneity among studies was evaluated with the I² statistic.

Results

A total of 367 patients were analyzed across three randomized controlled trials (183 patients receiving intravenous edaravone; 184 receiving placebo). A difference in ALSFRS-R score between groups at 24 weeks was found (mean difference [MD] = 1.63, 95% confidence interval [CI] 0.26–3.00, P = .02). No differences in the frequency of adverse events (odds ratio [OR] = 1.22, 95% CI 0.68–2.19, P = .50) or serious adverse events (OR = 0.71, 95% CI 0.43–1.19, P = .20) were found.

Conclusion

Intravenous edaravone is efficacious in amyotrophic lateral sclerosis patients, with no severe adverse effects. Additional reliable randomized controlled trials with larger sample sizes will further assess the efficacy and safety of edaravone in amyotrophic lateral sclerosis.

Clinical trial registration

The systematic review and meta-analysis was registered in the international prospective register of systematic reviews. (PROSPERO registration number: CRD42018096191; http://www.crd.york.ac.uk/PROSPERO.)

Available only for authorised users

Kiernan MC, Vucic S, Cheah BC, Turner MR, Eisen A, Hardiman O, Burrell JR, Zoing MC (2011) Amyotrophic lateral sclerosis. Lancet 377(9769):942–955CrossRef

Barber SC, Mead RJ, Shaw PJ (2006) Oxidative stress in ALS: a mechanism of neurodegeneration and a therapeutic target. Biochim Biophys Acta 1762(11–12):1051–1067CrossRef

Taylor JP, Brown RJ, Cleveland DW, Decoding ALS (2016) From genes to mechanism. Nature 539(7628):197–206CrossRef

Katyal N, Govindarajan R (2017) Shortcomings in the current amyotrophic lateral sclerosis trials and potential solutions for improvement. Front Neurol 8:521CrossRef

Chio A, Logroscino G, Hardiman O, Swingler R, Mitchell D, Beghi E, Traynor BG (2009) Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler 10(5–6):310–323CrossRef

Petrov D, Mansfield C, Moussy A, Hermine O (2017) ALS Clinical trials review: 20 years of failure. Are we any closer to registering a new treatment? Front Aging Neurosci 9:68CrossRef

Miller RG, Mitchell JD, Moore DH (2012) Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane Database Syst Rev (3):CD1447

Watanabe K, Tanaka M, Yuki S, Hirai M, Yamamoto Y (2018) How is edaravone effective against acute ischemic stroke and amyotrophic lateral sclerosis? J Clin Biochem Nutr 62(1):20–38CrossRef

Barnham KJ, Masters CL, Bush AI (2004) Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov 3(3):205–214CrossRef

10.

Liu Z, Zhou T, Ziegler AC, Dimitrion P, Zuo L (2017) Oxidative stress in neurodegenerative diseases: from molecular mechanisms to clinical applications. Oxidative Med Cell Longev 2017:2525967

11.

Duan W, Li X, Shi J, Guo Y, Li Z, Li C (2010) Mutant TAR DNA-binding protein-43 induces oxidative injury in motor neuron-like cell. Neuroscience 169(4):1621–1629CrossRef

12.

Zuo L, Zhou T, Pannell BK, Ziegler AC, Best TM (2015) Biological and physiological role of reactive oxygen species--the good, the bad and the ugly. Acta Physiol (Oxford) 214(3):329–348CrossRef

13.

Mitsumoto H, Santella RM, Liu X, Bogdanov M, Zipprich J, Wu HC, Mahata J, Kilty M, Bednarz K, Bell D, Gordon PH, Hornig M, Mehrazin M, Naini A, Flint BM, Factor-Litvak P (2008) Oxidative stress biomarkers in sporadic ALS. Amyotroph Lateral Scler 9(3):177–183CrossRef

14.

Geffard M, Mangas A, Bedat D, Covenas R (2018) GEMALS : A promising therapy for amyotrophic lateral sclerosis. Exp Ther Med 15(4):3203–3210PubMedPubMedCentral

15.

Ito H, Wate R, Zhang J, Ohnishi S, Kaneko S, Ito H, Nakano S, Kusaka H (2008) Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Exp Neurol 213(2):448–455CrossRef

16.

Tanaka M (2002) Pharmacological and clinical profile of the free radical scavenger edaravone as a neuroprotective agent. Nihon Yakurigaku Zasshi 119(5):301–308CrossRef

17.

Fujisawa A, Yamamoto Y (2016) Edaravone, a potent free radical scavenger, reacts with peroxynitrite to produce predominantly 4-NO-edaravone. Redox Rep 21(3):98–103CrossRef

18.

Aoki M, Warita H, Mizuno H, Suzuki N, Yuki S, Itoyama Y (2011) Feasibility study for functional test battery of SOD transgenic rat (H46R) and evaluation of edaravone, a free radical scavenger. Brain Res 1382:321–325CrossRef

19.

Yoshino H, Kimura A (2009) Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (phase II study). Amyotroph Lateral Scler 7(4):247–251CrossRef

20.

Nagase M, Yamamoto Y, Miyazaki Y, Yoshino H (2016) Increased oxidative stress in patients with amyotrophic lateral sclerosis and the effect of edaravone administration. Redox Rep 21(3):104–112PubMed

21.

Abe K, Aoki M, Tsuji S, et al. (2017) Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trials. Lancet Neurol 16(7):505–512

22.

Abe K, Itoyama Y, Sobue G, Tsuji S, Aoki M, Doyu M, Hamada C, Kondo K, Yoneoka T, Akimoto M, Yoshino H (2014) Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener 15(7–8):610–617CrossRef

23.

Abe K, Itoyama Y, Tsuji S, et al. (2017) Exploratory double-blind, Parallel-group, placebo-controlled study of edaravone (MCI-186) in amyotrophic lateral sclerosis (Japan ALS severity classification: grade 3, requiring assistance for eating, excretion or ambulation). Amyotroph Lateral Scler Frontotemporal Degener 18(sup1):40–48

24.

Lundh A, Gotzsche PC (2008) Recommendations by Cochrane review groups for assessment of the risk of bias in studies. BMC Med Res Methodol 8:22CrossRef

25.

Higgins JPT, Green S. Cochrane handbook for systematic reviews of interventions version 51.0. Available at: http://handbook.cochrane.org/.2011

26.

(1996) The Amyotrophic Lateral Sclerosis Functional Rating Scale. Assessment of activities of daily living in patients with amyotrophic lateral sclerosis. The ALS CNTF treatment study (ACTS) phase I-II study group. Arch Neurol 53(2):141–147

27.

Kasarskis E, Shefner J, Miller R (1999) A controlled trial of recombinant methionyl human BDNF in ALS: The BDNF study group (phase III). Neurology 52(7):1427–1433

28.

Ohashi Y, Tashiro K, Itoyama Y, Nakano I, Sobue G, Nakamura S, Sumino S, Yanagisawa N (2001) Study of functional rating scale for amyotrophic lateral sclerosis: revised ALSFRS (ALSFRS-R) Japanese version. No To Shinkei 53(4):346–355PubMed

29.

Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, Nakanishi A (1999) The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS study group (phase III). J Neurol Sci 169(1–2):13–21CrossRef

30.

Simpson EP, Henry YK, Henkel JS, Smith RG, Appel SH (2004) Increased lipid peroxidation in sera of ALS patients: a potential biomarker of disease burden. Neurology 62(10):1758–1765CrossRef

31.

D’Amico E, Factor-Litvak P, Santella RM, Mitsumoto H (2013) Clinical perspective on oxidative stress in sporadic amyotrophic lateral sclerosis. Free Radic Biol Med 65:509–527CrossRef

Title: Efficacy and safety of edaravone in treatment of amyotrophic lateral sclerosis—a systematic review and meta-analysis
Authors: Linting Luo
Zhibin Song
Xiaoqiang Li
Huiwang
Yaqing Zeng
Qinwang
Meiqi
Jianli He
Publication date: 01-02-2019
Publisher: Springer International Publishing
Published in: Neurological Sciences / Issue 2/2019
Print ISSN: 1590-1874
Electronic ISSN: 1590-3478
DOI: https://doi.org/10.1007/s10072-018-3653-2

At a glance: The STEP trials

Springer Medicine

Efficacy and safety of edaravone in treatment of amyotrophic lateral sclerosis—a systematic review and meta-analysis

Abstract

Background

Methods

Results

Conclusion

Clinical trial registration

At a glance: The STEP trials

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Clinical trial registration

Please log in to get access to this content

Other articles of this Issue 2/2019

Prepulse modulation and recovery of trigemino-cervical reflex in normal subjects

Influential factors and clinical significance of an atypical presentation of posterior reversible encephalopathy syndrome in patients with eclampsia

Dramatic improvement by levodopa treatment in a patient with vascular parkinsonism

The performance of patients with Parkinson’s disease on the Face-Name Associative Memory Examination

Observing movement disorders: best practice proposal in the use of video recording in clinical practice

Correction to: Efficacy of safinamide on non-motor symptoms in a cohort of patients affected by idiopathic Parkinson’s disease